Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer

Inclusion Criteria

• •Eligibility criteria
• •Histologically documented adenocarcinoma of the breast
• •ANC \> 1000 cells
• •Female; age \> 18
• •Zubrod PS 0-1
• •Platelets \> 100,000
• •Stage IIA-IIIB disease
• •Total bilirubin \< 1.5 ULN
• •No evidence of any metastatic disease
• •Serum Creatinine \< 1.5 gm/dl
• •No prior systemic therapy for breast cancer or Creat Cl \> 30 ml/min
• •Not pregnant or lactating
• •Serum ALT \< 2.0 ULN
• •ER, PR and HER2 status required
• •LVEF (MUGA/echo WNL)
• •No baseline \> 2 neuropathy
• •Urine protein: creat ratio \< 1.0
• •HER2-negative - either IHC 0-1+ or FISH ratio \< 2.0
• •Hemoglobin \> 9 gm/dl
• •(FISH testing is required for all HER2 2-3+ tumors by IHC)